Search Orphan Drug Designations and Approvals
-
Generic Name: | 2,5-dimethyl-3-[2-methyl-4-(methyloxy)phenyl]-N-[(1S)-1-(3-methyl-1,2,4-oxadiazol-5- |
---|---|
Date Designated: | 01/15/2015 |
Orphan Designation: | Treatment of congenital adrenal hyperplasia (CAH) |
Orphan Designation Status: | Designated/Designation Withdrawn or Revoked |
Date Designation Withdrawn or Revoked: | 02/16/2016 |
FDA Orphan Approval Status: | Not FDA Approved for Orphan Indication |
Sponsor: |
Neurocrine Biosciences, Inc. 12780 El Camino Real San Diego, California 92130 United States The sponsor address listed is the last reported by the sponsor to OOPD. |
*Data for the Date Designation Withdrawn or Revoked field are shown for designations withdrawn or revoked after 08/12/2013.
-